Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LaFleur Minerals Announces MOU with Granada Gold on Milling Assessment (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.


NDAQ:BCRX - Post by User

BioCryst Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(292)
•••
  • whytestocksX
Post by whytestockson Nov 04, 2024 7:00pm
54 Views
Post# 36296222

BioCryst Reports Third Quarter 2024 Financial Results and Pr

BioCryst Reports Third Quarter 2024 Financial Results and Pr
NEWS: $BCRX BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update&#x2014; Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) &#x2014; &#x2014; Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) &#x2014; &#x2014; Company introduces full-year 2024 total product reve...BCRX - BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities